**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 64949

**Manuscript Type:** REVIEW

**Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer**

Joechle K *et al.* mTORC2 in liver cancer

Katharina Joechle, Jessica Guenzle, Claus Hellerbrand, Pavel Strnad, Thorsten Cramer, Ulf Peter Neumann, Sven Arke Lang

**Katharina Joechle,Thorsten Cramer, Ulf Peter Neumann, Sven Arke Lang,** Department of General, Visceral and Transplantation Surgery, University Hospital Rheinisch-Westfälisch Technische Hochschule Aachen, Aachen 52074, Germany

**Jessica Guenzle,** Department of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany

**Claus Hellerbrand,** Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91054, Germany

**Pavel Strnad,** Department of Internal Medicine III, University Hospital Rheinisch-Westfälisch Technische Hochschule Aachen, Aachen 52074, Germany

**Author contributions:** Joechle K and Lang SA contributed to conception and design the article; Joechle K, Hellerbrand C and Strnad P contributed to acquisition of data, drafting the article; All authors contributed to critical revision for important content and approved the final manuscript.

**Supported by** the German Research Council (Deutsche Forschungsgemeinschaft, DFG; FOR2127; LA1988/4-2) (to Lang SA and Hellerbrand C).

**Corresponding Author: Sven Arke Lang, FEBS, MD, Professor, Senior Researcher, Surgeon,** Department of General, Visceral and Transplantation Surgery, University Hospital Rheinisch-Westfälisch Technische Hochschule Aachen, Pauwelsstraße 30, Aachen 52074, Germany. svlang@ukaachen.de

**Received:** February 25, 2021

**Revised:** April 30, 2021

**Accepted:** August 16, 2021

**Published online:**

**Abstract**

The mammalian target of rapamycin (mTOR) acts in two structurally and functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Upon deregulation, activated mTOR signaling is associated with multiple processes involved in tumor growth and metastasis. Compared with mTORC1, much less is known about mTORC2 in cancer, mainly because of the unavailability of a selective inhibitor. However, existing data suggest that mTORC2 with its two distinct subunits Rictor and mSin1 might play a more important role than assumed so far. It is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism and cytoskeletal organization. It is not only implicated in tumor progression, metastasis, and the tumor microenvironment but also in resistance to therapy. Rictor, the central subunit of mTORC2, was found to be upregulated in different kinds of cancers and is associated with advanced tumor stages and a bad prognosis. Moreover, AKT, the main downstream regulator of mTORC2/Rictor, is one of the most highly activated proteins in cancer. Primary and secondary liver cancer are major problems for current cancer therapy due to the lack of specific medical treatment, emphasizing the need for further therapeutic options. This review therefore summarizes the role of mTORC2/Rictor in cancer, with special focus on primary liver cancer but also on liver metastases.

**Key Words:** Mammalian target of rapamycin; Mammalian target of rapamycin complex 2; Rictor; Liver cancer; Liver metastases; Hepatocellular carcinoma; Cholangiocellular carcinoma

Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA. Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. *World J Gastrointest Oncol* 2021; In press

**Core Tip:** Mammalian target of rapamycin complex 2 (mTORC2) has recently gained importance in cancer research, as it is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism and cytoskeletal organization. Rictor, the central subunit of mTORC2, was found to be upregulated in different kinds of cancers and is associated with a bad prognosis. We herein discuss the implications of mTORC2 in primary and secondary liver cancer.

**INTRODUCTION**

The mammalian target of rapamycin (mTOR) is an atypical serine/threonine kinase which controls cell survival, proliferation, and metabolism through phosphorylation of its downstream targets. It acts in two structurally and functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), and can be activated by several stimulating factors as hypoxia, insulin, growth factors or dysregulation of PI3K/Akt signaling[1,2]. However, upon deregulation, activated mTOR signaling is implicated in the hallmarks of cancer and associated with increased cell survival, uncontrolled cell proliferation, metabolic reprogramming, and aberrant angiogenesis[3], which makes it a promising target in anticancer therapy.

The incidence of primary liver cancer, such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (iCCC), is increasing worldwide. Systemic therapy options are limited for both cancer entities. Surgery offers the only chance for cure, although only a minority of patients with HCC or iCCC are eligible for resection. Moreover, the liver is one of the most frequent sites of metastases development. Indeed, in most cancer entities liver metastasis is associated with a dramatic decline of patient’s prognosis, further emphasizing the fundamental impact of this site. A deeper understanding of processes involved in either primary or secondary liver cancer is therefore urgently needed[4-6].

Due to the availability of (more or less) selective mTORC1 targeting agents such as rapamycin, the role of mTORC1 in cancer has been extensively studied for decades. In contrast, mTORC2 was less intensively analyzed, mainly because of the lack of selective pharmacologic inhibitors. However, the last decade has brought up several studies suggesting a role for mTORC2 in cancer. For instance, Rictor (rapamycin insensitive companion of TOR), the central subunit of mTORC2, was found to be upregulated in different kinds of cancer and is associated with impaired prognosis[7-10]. Evidence from primary and secondary liver cancer are summarized in Table 1. In addition, involvement of mTORC2/Rictor in a plethora of processes involved in tumor growth and also metastasis have been reported[11]. Therefore, the present review summarizes the current knowledge regarding the role of mTORC2 in cancer with focus on primary and secondary liver cancer.

**mTOR complexes and signaling**

Although mTOR acts through the different complexes mTORC1 and mTORC2, both have several subunits in common, the catalytic kinase mTOR, the scaffolding protein mLST8, the regulatory subunit DEPTOR, and the stabilizing complex Tti1/Tel2. The distinct subunits of mTORC1 are Raptor and PRAS40. While Raptor is important for mTORC1 substrate specificity, stability, and regulation, PRAS40 acts as negative regulator of mTORC1. Activation of mTORC1 depends on nutrient (*e.g.,* amino acids) and growth factor (*e.g.,* insulin) signaling through the PI3K/AKT and Ras-MAPK cascades. Phosphorylated AKT (*via* the PI3K/AKT pathway) or ERK and RSK (*via* the Ras-MAPK cascade) inhibit the TSC1/2 complex, which in turn triggers RHEB-mediated activation of mTORC1 leading to phosphorylation of its substrates 4EBP1 and S6K1. The downstream effectors act as key regulators of cap-dependent and cap-independent mTORC1 translation[3] and regulate translation and transcription of different target genes (*e.g.,* HIF1α, *etc.*) thereby being implicated in cell growth, proliferation and metabolism[12].

mTORC2 consists of its specific subunits Rictor and mSin1. Similar to Raptor, Rictor controls mTORC2 stability, subcellular localization and substrate identification. It is essential for mTORC2 function, as silencing Rictor leads to significant inhibition of AKT, the key substrate of mTORC2. mSin1 negatively regulates mTORC2 until PI3K-mediated growth factor signaling locates mSin1/mTORC2 to the plasma membrane and relieves its inhibition. In turn, PI3K-generated PIP3 activates mTORC2. Activated mTORC2/Rictor leads to phosphorylation of AKT at the Ser473 residue. AKT can also be phosphorylated at the Thr308 residue by PDK1, which is in turn attracted by PIP3. Importantly, AKT is one of the most frequently activated proteins in cancer, and its full activity is only achieved if both sites are phosphorylated[13,14]. On a functional level, AKT is involved in many processes. Association with cell migration, invasion, increased tumor growth, and cell survival while inhibiting apoptosis and promoting proliferative processes including glucose uptake and glycolysis have been described[15,16]. Additional substrates of mTORC2 are the AGC kinases like the PKC (*e.g.,* PKCα, PKCδ, PKCε) family, which control tumorigenesis, cell migration and cytoskeletal remodeling, and SGK isoforms that are implicated in cell survival and resistance to chemotherapy.

Along with the essential role of Rictor for mTORC2 functioning, it also acts independently of mTORC2. Thr1135, one of the 37 phosphorylation sites of Rictor, was shown to be stimulated directly by growth factor signaling and to be sensitive to rapamycin, as it is targeted by S6K1, one of the downstream effectors of mTORC1[17,18]. This mechanism is assumed to represent a regulatory link between mTORC1 and mTORC2 signaling and to be part of a reciprocally influenced feedback loop mechanism[19,20]. Moreover, Rictor was also described to be associated with complexes exhibiting oncogenic and tumor suppressor properties. For example, Rictor forms a complex with ILK, which is crucial for TGFß1 mediated epithelial-to-mesenchymal transition (EMT) and cancer cell survival[16,21]. In contrast, the combination of Rictor with PCD4 acts in an anti-oncogenic manner, as renal cancer cells showed reduced metastatic ability[22].

**Implications of mTORC1 in cancer**

Besides being implicated in many physiological processes such as glucose and lipid homeostasis, adipogenesis, maintaining muscle mass and function, brain and immune function, deregulation of mTORC1 signaling is not only associated with diseases such as diabetes, neurodegeneration, and cancer. As described above, mTORC1 is activated by the oncogenic pathways PI3K/Akt and Ras-MAPK cascade. However, the oncogenic pathways are frequently mutated, resulting in hyperactivation of mTORC1, which is found in many human cancers[1]. Hyperactivated mTORC1 and its association with tumorigenesis is also seen in tuberous sclerosis, a familial cancer syndrome defined by the loss of the TSC1/2 complex, a negative regulator of mTORC1. Downstream of mTORC1, its role in carcinogenesis is linked to metabolic reprogramming in cancer cells. One example is the Warburg effect; aerobic glycolysis is controlled by mTORC1 *via* increased translation of HIF1α that in turn regulates expression of glycolytic enzymes[23]. mTORC1 is also associated with upregulation of genes involved in lipogenesis by activation of the transcription factor SREBP1 through phosphorylation of Lipin1 and S6K1[24,25]. The latter was shown to be a major mechanism to promote growth and proliferation in breast cancer cells[26]. mTORC1-mediated phosphorylation of S6K1 is not only involved in lipogenesis but also in purine and pyrimidine synthesis leading to a rapid DNA duplication in cancer cells[27,28]. Aside from its control in cancer cell metabolism, mTORC1 is also involved in regulation of autophagy and macropinocytosis.

The implications of mTORC1 in cancer are widely studied because of the availability of rapamycin as a selective mTORC1 inhibitor. However, rapamycin analogs (rapalogs) have only shown limited efficacy in cancer therapy. While inhibition of mTORC1 by rapamycin blocks phosphorylation of S6K1, phosphorylation of 4EBP1 is not fully blocked[29]. Therefore, 4EBP1-regulated translation of proteins involved in tumorigenesis is not inhibited. Another reason for the limited efficacy of rapamycin and rapalogs is explained by a compensatory upregulation of AKT through phosphorylation of its Thr308 and Ser473 residue[30,31] as inactivated S6K1 no longer prevents suppression of insulin-PI3K signaling[32,33]. Moreover, treatment with rapalogs may increase micropinocytosis and autophagy leading to enhanced cell proliferation and survival[34,35].

**Implications of mTORC2 in cancer**

Compared with mTORC1, much less is known about the role of mTORC2 in cancer, although existing data suggests mTORC2 to be of importance. Particularly, it is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism and cytoskeletal organization.

***Tumorigenesis***

As described above, AKT is the key downstream target of mTORC2 signaling and one of the most commonly activated proteins in cancer[36,37] with its isoforms AKT1 and AKT2 being the main effectors in tumorigenesis[38]. With more than 200 AKT substrates, the different isoforms seem to have unique roles in tumorigenesis. While AKT1 increases tumor development and reduces tumor invasion, expression of AKT2 has the opposite effect[39]. Frequently, hyperactivated AKT is found in different kind of cancers. For example, hyperactivation of AKT caused by a somatic mutation was found to induce B-cell lymphoma, in contrast to wild-type AKT[40]. The somatic mutation was also found in breast, colorectal, and ovarian cancer. In addition to somatic mutations, hyperactivation of AKT may also occur because of activating upstream mutations in PI3K or deletions in PTEN, a tumor suppressor[41]. AKT has several substrates in common with SGK family members, another downstream target of mTORC2. Hence, SGK is similarly implicated in cell growth and proliferation[42]. Its isoform SGK3 is dependent on PDK1 signaling to induce tumor growth and adopted the role of AKT in tumorigenesis in PI3K mutated cancer cells[43]. AKT and SGK, which are different isoforms of PKC, are also involved in tumorigenesis. PKC-ε, PKC-λ/ι, and PKC-β are known oncogenes with PKC-λ/ι and PKC-β for example being involved in colon carcinogenesis[44,45]. Mechanisms by which mTORC2 is involved in tumorigenesis are shown in Figure 1.

***Metastasis***

Cell migration and invasion are the two key components of metastasis that are affected by mTORC2 through different pathways. On the one hand, phosphorylation of AKT leads to activation of Rac1 through activation of Tiam1[46]. On the other hand, Rac1 is also upregulated by the suppression of its inhibitor RhoGD12, not only through AKT, but also independent of AKT through PKCα activation[46,47] (Figure 2). Rac1 and RhoA are small GTPases known to have crucial roles in actin cytoskeletal rearrangement and cell migration, mainly by stimulating lamellipodia formation[48]. Upon mTORC2 knockdown, expression of Rac1 and RhoA is decreased, leading to a reduction of colorectal metastasis[49]. AKT1 is thus the AKT isoform implicated in metastasis. Silencing only AKT1 and not AKT2 reduces migration and invasion[50]. The gain of invasive behavior is explained by the EMT, and was reversible upon mTORC2 and mTORC1 inhibition, which was followed by increase in cell-cell contacts and E-cadherin; vimentin, SMA, fibronectin, and MMP9 decreased[49].

***Metabolic reprogramming***

Metabolic reprogramming, is a hallmark of cancer, and it allows tumor cells to receive and maintain their energy supply for rapid tumor growth[51]. mTORC2 was shown to control c-Myc, a regulator of the Warburg effect, by phosphorylation of class IIa HDAC and acetylation of FoxO in both an AKT dependent and independent manner, thereby increasing glycolysis[52]. Increases of glucose and acetate cause acetylation of Rictor, which in turn maintains mTORC2 signaling[53]. Besides glycolysis, mTORC2 also controls cystine uptake and glutathione metabolism. Phosphorylation of SLC7A11 thereby allows tumor cells to focus mainly on survival rather than proliferation if the extracellular environment changes[54]. In addition to energy supply, metabolic reprogramming can also be involved in drug resistance, as mTORC2 was shown to act as a central link between glucose metabolism and resistance to EGFR tyrosine kinase inhibitors[55].

***Drug resistance***

As mentioned above, metabolic reprogramming is one of the mechanisms of mTORC2-mediated drug resistance in cancer cells. Glucose metabolism has been linked not only to resistance to EGFR tyrosine kinase inhibitors[55] but also has caused Rictor acetylation that can be achieved by either glucose or acetate. Rictor acetylation induces auto-activation of mTORC2 signaling despite the absence of upstream growth factor signaling leading to resistance to EGFR-, PI3K- and AKT-targeted therapies[56]. Furthermore, Rictor utilizes inhibition of apoptosis by activation of NF-κB as another mechanism to develop resistance to chemotherapy[57]. Interestingly, the process could be overcome only by Rictor and not by AKT inhibition, suggesting that NF-κB is an AKT-independent mTORC2 downstream effector. In contrast, the positive feedback mechanism between amplified Rictor, known to occur in many cancers, and AKT leads to constant AKT activation, inducing not only tumor progression but also drug resistance[11].

**mTORC2 in primary liver cancer**

***Hepatocellular carcinoma***

HCC is the most common primary liver cancer and one of the main cancer-related deaths worldwide, with increasing incidence in recent years[58]. Systemic treatment options, with the multikinase inhibitors sorafenib and lenvatinib as the only approved drugs, are very limited in case of unresectability or unavailability to local treatment options. Activation of mTORC2 as determined by immunohistochemistry of phospho-AKT was detectable in 60% of HCCs[59]. Chromosomal gain of Rictor was described in 25% of HCCs, and its high expression was associated with a poor prognosis in HCC patients[60]. Similarly, Kaibori *et al*[61]found high expression of Rictor mRNA and protein and association with Rictor/Raptor ≥ 0,3 was a prognostic factor indicating poor recurrence-free survival. Rictor knockdown was shown to inhibit HCC cell growth *in vitro*[62], and AKT overexpression *in vivo* led to increased HCC development[63]. In the liver, there are two AKT isoforms, AKT1 and AKT2. Only AKT1 is phosphorylated and is thus activated by mTORC2 in c-Myc-induced HCC. AKT1 was the main driver of HCC formation, as AKT1 inhibition completely abolished c-Myc-induced tumor development[60]. Silencing of Rictor also led to inhibition of c-Myc-induced HCC formation[60]. In contrast, inhibition of AKT2 significantly reduced loss of PTEN-induced HCC formation[64]. Moreover, it was found that loss of Rictor completely inhibited sgPTEN/c-Met HCC formation, leading to the assumption that mTORC2 regulates different AKT isoforms in HCC tumor development[65]. In contrast, the role of the other mTORC2 substrates, PKC and SGK in HCC, remains poorly characterized. However, mTORC2 also impacts HCC tumorigenesis through its role in metabolic reprogramming. Fatty acid and lipid synthesis are triggered by mTORC2 thereby leading to hepatic steatosis and tumor development[66]. The causal context was proven, as HCC development was completely abolished upon inhibition of fatty acid or sphingolipid synthesis[66]. Not only mTORC2-associated lipid synthesis but also gluconeogenesis impacts on HCC cell survival. Khan *et al*[67] showed that blocking mTORC2 led to increased gluconeogenesis and decreased HCC cell proliferation and survival. In addition to the important role of mTORC2 in hepatocarcinogensis it also seems to be involved in HCC metastasis and drug resistance. CHKA is an enzyme known to be associated with HCC metastasis and EGFR-resistance. Inhibition of Rictor completely abolished CHKA-enhanced cell migration and invasion[8]. In line with that, pharmacologic mTORC1/mTORC2 inhibition reduced tumor cell metastasis, while there was no effect shown if the mTORC1 inhibitor rapamycin was used[8]. Moreover, following Rictor knockdown, CHKA-mediated resistance of HCC cells to EGFR-inhibitors decreased, and sensitivity to the drugs increased[8]. Similarly, the dual mTORC1/mTORC2 inhibitor OSI-027 reversed high MDR1 expression in HCC induced by doxorubicin and therefore increased chemosensitivity of doxorubicin. Combining both drugs led to inhibition of tumor growth *in vitro* and *in vivo*[68]. In that context, the investigators concluded that mTORC2 was the component responsible for the effect, as inhibition of mTORC1 alone resulted in a modest decrease of MDR1 expression.

While these data show an important role of mTORC2/Rictor in the tumorigenesis and tumor progression of HCC, it is involved in pre-tumor conditions. For example, Reyes-Gordillo *et al*[69]showed that the AKT isoforms were activated in an *in vivo* two-hit model of alcoholic liver disease, leading to an increase of mTORC2 and inflammatory, proliferative, and fibrogenic genes. In line with the results, blocking of AKT1 and AKT2 led to a decrease in progression of liver fibrosis. In addition, mTORC2 was involved in the progression of nonalcoholic fatty liver disease (NAFLD) by dysregulation of white adipose tissue. Thereby, *de novo* lipogenesis, lipolysis, glycolysis, and increased glucose uptake by GLUT-4 are the mechanisms by which mTORC2 regulates adiposity and NAFLD[70]. Besides alcoholic and nonalcoholic liver disease, viral hepatitis is one of the main risk factors for development of HCC. In that context, increased AKT activity was demonstrated for hepatitis B and C. In hepatitis B, activation of AKT by the hepatitis B virus protein HBx leads to a persistent, noncytopathic virus replication[71]. In hepatitis C, its NS3/4A protease increases AKT activity by enhancing EGF-induced signal transduction[72].

***Intahepatic cholangiocarcinoma***

iCCC is a highly aggressive tumor entity with increasing incidence in recent years[73]. As systemic treatment only has partial benefits in advanced stages of iCCC[74], surgical resection remains the only curative option. Only a few studies examining the role of mTORC2 in iCCC exist. mTORC2 was found to be activated in almost 70% of iCCCs as determined by immunohistochemistry of phospho-AKT[75]. When examining the AKT isoforms, protein expression of phospho-AKT1 was shown in 34% of patients with iCCC and was associated with a favorable prognosis[76]. This unexpected result might be dependent on the mechanism of AKT activation triggering different downstream targets or a potential distinct role of AKT1 in iCCC. However, after Rictor knockdown, growth of iCCC cells *in vitro* was impaired and activated AKT was shown to cooperate with YAP to induce iCCC in mice[75]. Moreover, in liver-specific Rictor knockout mice, cholangiocarcinogenesis induced by AKT/YapS127A was completely abolished, while wild-type mice had a lethal tumor burden at the same time point[75]. Therefore, Zhang *et al*[77] used the pan-mTOR inhibitor MLN0128 and noticed significantly increased apoptosis but only slight effects on proliferation in iCCC *in vitro* and *in vivo*. Significantly enhanced apoptosis and consequently impaired cell proliferation in iCCC was also found after siRNA-mediated Rictor knockdown and simultaneous treatment with sorafenib *via* increase of FoxO1. Wang *et al*[78] reported another mechanism of tumorigenesis, which supported the oncogenic potential of mTORC2 signaling in iCCC. Briefly, activated AKT in combination with downregulation of the tumor suppressor FXBW7, increased cholangiocarcinogenesis. Interestingly, silencing cMyc in AKT/Fbxw7ΔF mice completely impaired iCCC growth[78]. Furthermore, the results of a study by Yang *et al*[79] examining the impact of FXBW7 on EMT and metastasis of iCCC and perihilar CCC (pCCC) is also interesting even though it did not directly connect FXBW7 to mTORC2. In that study, silencing of FXBW7 lead to promotion of EMT, stem-like property, and metastasis of iCCC and pCCC.

While mTORC2 also seems to be also involved in the pre-tumoral conditions of HCC including (non) alcoholic liver disease and viral hepatitis, no data exist on the role of mTORC2 chronic cholangitis, primary or secondary biliary cirrhosis as risk factors for the development of iCC. In summary, mTORC2/Rictor seems to play a role in the development and progression of HCC and iCCC *via* different mechanisms (Figure 3). However, more research is necessary to determine its exact role and to define potential targets for antineoplastic therapy.

**mTORC2 in secondary liver cancer**

***Colorectal cancer liver metastasis***

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths[80], with liver metastases being one of the most important predictors of worse long-term outcome. While it was shown that Rictor mRNA and protein are overexpressed in CRC[49] and expression is correlated with tumor progression, Dukes stage, lymph node metastasis, and impaired overall survival[10,81], there was no difference in Rictor expression between primary tumors and metastatic liver lesions[49]. However, Rictor expression in primary tumors with metastatic liver lesions was significantly higher than it was in primary tumors without metastatic disease[49]. Further not only Rictor but also Raptor seem to be involved in colorectal liver metastases (CRLM), as knockdown of Rictor as well as knockdown of Raptor led to decreased migration and invasion of colorectal cancer cells *in vitro*[49]. In addition, *in vivo* knockdown of Raptor and Rictor in CRC cell lines impaired the formation of even micrometastases[49]. A study by Gulhati *et al*[49] did not focus on the development of liver metastases, but they showed that mTORC2 *via* Rictor regulated actin cytoskeleton reorganization and cell migration through Rac1 and RhoA signaling. However, that is not the only mTORC2-associated mechanism involved in the formation of CRLM. TELO2, known to be essential for mTOR complex integrity, was found to be associated with colorectal tumorigenesis, migration, and invasion, as Rictor knockdown led to reduced TELO2-induced migratory and invasive behavior of colorectal cancer cells[82]. Moreover, colorectal metastasis is not controlled only *via* Rictor but also by mSin1. Wang *et al*[83] showed that the tumor suppressor Pdcd4 inhibited Sin1 translation leading to reduced mTORC2 activation and inhibited invasion of CRC cells. While the studies support the important oncogenic and metastatic potential of mTORC2 in CRC, it is also involved in resistance to systemic chemotherapeutic agents[81]. In particular, resistance of CRC cells to irinotecan, one of the three drugs of FOLFIRI, was resolved by treatment with mTORC1/2 inhibitors. Reita *et al*[84] demonstrated that the combination of irinotecan and an mTORC1/2 blocker reduced migration and invasion *in vitro* as well as the development of liver metastases *in vivo* more effectively than irinotecan alone. Consistently, the knockdown of Rictor increased the sensitivity to irinotecan in SMAD4-negative colon cancer cells[85].

***Breast cancer liver metastasis***

Breast cancer accounts for almost one in four cancer cases among women, thereby representing the leading cause of cancer in over 100 countries worldwide[80]. Ma *et al*[86] recently reviewed the evidence that after the bony skeleton and the lung, breast cancer metastasizes most often to the liver, leading to very limited survival if untreated. Although many systemic therapies exist for metastatic breast cancer, overactive PI3K/AKT/mTOR signaling was shown be associated with resistance to therapy and with tumor progression[87-89]. The findings revealed 92% Rictor positivity in breast cancer lymph node metastases[90] as well as decreased tumor growth and migration but increased apoptosis upon Rictor knockdown[91]. Functionally, different pathways of mTORC2/Rictor involvement in breast cancer metastasis have been described. mTORC2 activates Rac1 through AKT phosphorylation and PKC-dependent downregulation of RhoGD12 leading to increased invasion and migration[46]. Rac1 is also activated by IBP, which was shown to regulate migration and invasion as well as actin cytoskeleton rearrangement and matrix metalloprotease production in breast cancer cells[92] by activation of the mTORC2/AKT/FoxO3a signaling pathway[93]. Moreover, interactions between mTORC2 and PRICKLE1 were shown to control cancer cell dissemination and motility[94]. Similarly, Rictor interacts with PKC-ζ to regulate breast cancer metastasis[90]. mTORC2 is further implicated in EMT in breast cancer by regulation of Snail and TGFß to control migration and invasion[21,95].

***Melanoma liver metastasis***

Melanoma liver metastasis occurs in up to 20% of patients with cutaneous melanoma and is one of the main prognostic factors of poor survival[96,97]. mTORC2/Rictor is not only involved in PI3K dependent melanoma development[98] and metabolic reprogramming[99] but also in melanoma liver metastases. Rictor mRNA and protein were shown to be overexpressed in invasive melanoma[100] and to be significantly enhanced in metastatic compared with nonmetastatic melanoma[101]. Consistent with those findings, siRNA-mediated Rictor knockdown as well as pharmacological inhibition of mTORC2 not only led to reduced tumor cell motility, migration and invasion *in vitro*[100,101] but also reduced melanoma liver metastasis *in vivo[*101,102]. Rictor depletion was shown to reduce AKT phosphorylation at the Ser473 and Thr308 residues and to inhibit expression of MMP-2 and MMP-9[100,102]. Moreover, upon Rictor inhibition, interaction with stromal components such as hepatic stellate cells and HGF-induced melanoma cell activation/motility were impaired[101].

***Renal cancer liver metastasis***

Liver metastases occur in about one fifth of patients with metastatic renal cancer[103], and surgical therapy remains the only strategy to improve survival. See Pinotti *et al*[104] for a review. However, mTORC2 signaling might be a potential therapeutic target, as it is involved in the formation of renal cancer liver metastasis. Sun *et al*[105] showed that the proinflammatory cytokines TNFα and IL-6 increased upregulation of Rictor through the NF-κB pathway, thereby enhancing chemotaxis, invasion, and migration of renal cancer cells. Upon Rictor knockdown, the formation of renal cancer liver and lung metastases was significantly reduced[105]. Increased migration and invasion was also associated with activation of mTORC2/Akt/GSK3β/β-catenin signaling through TCTP overexpression[106]. Furthermore, pharmacological mTORC2 inhibition led to reduced migration by regulation of HIF2α and increase of cell-cell-junctions *via* E-cadherin[107].

***Gastric and pancreatic cancer liver metastasis***

Gastric cancer is the third leading cause of cancer-related deaths worldwide[80] with the liver being the most common side of gastric cancer metastasis[108]. Similarly, pancreatic cancer is one of the most fatal diseases with a 5-year survival rate of only 7%[109]. Rictor expression in gastric tumor samples was shown to correlate with TNM stage, lymph node metastasis, and poor long-term outcome. Positive staining of Akt at the Ser473 residue was associated with distant metastasis[7,110]. Also, Wang *et al*[111] reported the role of mTORC2 in gastric cancer metastasis, as DDR2 was found to enhance invasion and EMT through mTORC2 activation and AKT phosphorylation. Upon Rictor knockdown, proliferation, migration, and invasion of gastric cancer cells were significantly reduced while apoptosis was enhanced[110]. Regarding pancreatic cancer, Rictor protein expression was associated overall survival after surgical resection. Patients with high or medium Rictor expression had a significantly shorter survival compared with those with low expression[9]. Upon siRNA-mediated Rictor knockdown, pancreatic tumor cell proliferation and vascularization were significantly impaired and a trend toward fewer liver metastases was observed[9].

**CONCLUSION**

Compared with mTORC1, little is known about the role of mTORC2 and its distinct subunit Rictor, in cancer. However, the present review underlines the importance and high relevance of mTORC2 not only in tumorigenesis of primary liver cancer but also in the formation of metastatic liver lesions with different primaries. Thereby, mTORC2/Rictor and AKT, its main downstream effector, are associated with various steps of the metastatic cascade, including EMT, migration and invasion, and angiogenesis, and tumor cell proliferation through different signaling pathways. However, a more refined understanding of the implications of mTORC2 in primary and secondary liver cancer is essential to convert this knowledge into the development of specific mTORC2 targeting therapies.

**REFERENCES**

1 **Saxton RA**, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell* 2017; **169**: 361-371 [PMID: 28388417 DOI: 10.1016/j.cell.2017.03.035]

2 **Lu X,** Paliogiannis P, Calvisi DF, and Chen X. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies. *Hepatology* 2020 [PMID: 32394479 DOI: 10.1002/hep.31310]

3 **Kim LC,** Cook RS, and Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. *Oncogene* 2017; **36**: 2191-2201 [PMID: 27748764 DOI: 10.1038/onc.2016.363]

4 **Forner A**, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]

5 **Valle JW,** Kelley RK, Nervi B, Oh DY, and Zhu AX. Biliary tract cancer. *Lancet* 2021; **397**: 428-444 [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7]

6 **Mejia JC**, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. *Surg Clin North Am* 2020; **100**: 535-549 [PMID: 32402299 DOI: 10.1016/j.suc.2020.02.013]

7 **Bian Y,** Wang Z, Xu J, Zhao W, Cao H, and Zhang Z. Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer. *Biochem Biophys Res Commun* 2015; **464**: 534-540 [PMID: 26159923 DOI: 10.1016/j.bbrc.2015.07.001]

8 **Lin XM,** Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, and Chen L. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. *Gastroenterology* 2017; 152: 1187-1202 [PMID: 28065789 DOI: 10.1053/j.gastro.2016.12.033]

9 **Schmidt KM**, Hellerbrand C, Ruemmele P, Michalski CW, Kong B, Kroemer A, Hackl C, Schlitt HJ, Geissler EK, Lang SA. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. *Oncotarget* 2017; **8**: 24491-24505 [PMID: 28445935 DOI: 10.18632/oncotarget.15524]

10 **Wang L,** Qi J, Yu J, Chen H, Zou Z, Lin X, and Guo L. Overexpression of Rictor protein in colorectal cancer is correlated with tumor progression and prognosis. *Oncol Lett* 2017; **14**: 6198-6202 [PMID: 29113267 DOI: 10.3892/ol.2017.6936]

11 **Zhao D**, Jiang M, Zhang X, Hou H. The role of RICTOR amplification in targeted therapy and drug resistance. *Mol Med* 2020; **26**: 20 [PMID: 32041519 DOI: 10.1186/s10020-020-0146-6]

12 **Shor B**, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. *Cell Cycle* 2009; **8**: 3831-3837 [PMID: 19901542 DOI: 10.4161/cc.8.23.10070]

13 **Liu P,** Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, and Wei W. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. *Cancer Discov* 2015; **5**: 1194-1209 [PMID: 26293922 DOI: 10.1158/2159-8290.CD-15-0460]

14 **Magaway C**, Kim E, Jacinto E. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. *Cells* 2019; **8** [PMID: 31817676 DOI: 10.3390/cells8121584]

15 **Bhaskar PT**, Hay N. The two TORCs and Akt. *Dev Cell* 2007; **12**: 487-502 [PMID: 17419990 DOI: 10.1016/j.devcel.2007.03.020]

16 **McDonald PC**, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ, Dedhar S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. *Cancer Res* 2008; **68**: 1618-1624 [PMID: 18339839 DOI: 10.1158/0008-5472.CAN-07-5869]

17 **Dibble CC**, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. *Mol Cell Biol* 2009; **29**: 5657-5670 [PMID: 19720745 DOI: 10.1128/MCB.00735-09]

18 **Boulbes D,** Chen CH, Shaikenov T, Agarwal NK, Peterson TR, Addona TA, Keshishian H, Carr SA, Magnuson MA, Sabatini DM, and Sarbassov dos D. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. *Mol Cancer Res* 2010; **8**: 896-906 [PMID: 20501647 DOI: 10.1158/1541-7786.MCR-09-0409]

19 **Dancey J**. mTOR signaling and drug development in cancer. *Nat Rev Clin Oncol* 2010; **7**: 209-219 [PMID: 20234352 DOI: 10.1038/nrclinonc.2010.21]

20 **Gkountakos A**, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, Tortora G, Scarpa A, Bria E, Corbo V. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. *Carcinogenesis* 2018; **39**: 971-980 [PMID: 29955840 DOI: 10.1093/carcin/bgy086]

21 **Serrano I**, McDonald PC, Lock FE, Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT). *Oncogene* 2013; **32**: 50-60 [PMID: 22310280 DOI: 10.1038/onc.2012.30]

22 **Bera A**, Das F, Ghosh-Choudhury N, Kasinath BS, Abboud HE, Choudhury GG. microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. *Exp Cell Res* 2014; **328**: 99-117 [PMID: 25016284 DOI: 10.1016/j.yexcr.2014.06.022]

23 **Düvel K**, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell* 2010; **39**: 171-183 [PMID: 20670887 DOI: 10.1016/j.molcel.2010.06.022]

24 **Peterson TR**, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. *Cell* 2011; **146**: 408-420 [PMID: 21816276 DOI: 10.1016/j.cell.2011.06.034]

25 **Porstmann T**, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab* 2008; **8**: 224-236 [PMID: 18762023 DOI: 10.1016/j.cmet.2008.07.007]

26 **Ricoult SJ**, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. *Oncogene* 2016; **35**: 1250-1260 [PMID: 26028026 DOI: 10.1038/onc.2015.179]

27 **Robitaille AM**, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, Prescianotto-Baschong C, Sauer U, Jenoe P, Hall MN. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. *Science* 2013; **339**: 1320-1323 [PMID: 23429704 DOI: 10.1126/science.1228771]

28 **Ben-Sahra I**, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. *Science* 2016; **351**: 728-733 [PMID: 26912861 DOI: 10.1126/science.aad0489]

29 **Benjamin D**, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. *Nat Rev Drug Discov* 2011; **10**: 868-880 [PMID: 22037041 DOI: 10.1038/nrd3531]

30 **Lang SA**, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. *Biochim Biophys Acta* 2010; **1803**: 435-442 [PMID: 20116405 DOI: 10.1016/j.bbamcr.2010.01.009]

31 **Lang SA,** Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, and Stoeltzing O. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. *Hepatology* 2009; **49**: 523-532 [PMID: 19085954 DOI: 10.1002/hep.22685]

32 **Um SH,** Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, and Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* 2004; **431**: 200-205 [PMID: 15306821 DOI: 10.1038/nature02866]

33 **Harrington LS**, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J Cell Biol* 2004; **166**: 213-223 [PMID: 15249583 DOI: 10.1083/jcb.200403069]

34 **Degenhardt K**, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 2006; **10**: 51-64 [PMID: 16843265 DOI: 10.1016/j.ccr.2006.06.001]

35 **Palm W**, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. *Cell* 2015; **162**: 259-270 [PMID: 26144316 DOI: 10.1016/j.cell.2015.06.017]

36 **Manning BD**, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007; **129**: 1261-1274 [PMID: 17604717 DOI: 10.1016/j.cell.2007.06.009]

37 **Engelman JA**, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet* 2006; **7**: 606-619 [PMID: 16847462 DOI: 10.1038/nrg1879]

38 **Xu K,** Liu P, and Wei W. mTOR signaling in tumorigenesis. *Biochim Biophys Acta* 2014; **1846**: 638-654 [PMID: 25450580 DOI: 10.1016/j.bbcan.2014.10.007]

39 **Dillon RL**, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer Res* 2009; **69**: 5057-5064 [PMID: 19491266 DOI: 10.1158/0008-5472.CAN-08-4287]

40 **Carpten JD,** Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, and Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 2007; **448**: 439-444 [PMID: 17611497 DOI: 10.2210/pdb2uzs/pdb]

41 **Schmelzle T**, Hall MN. TOR, a central controller of cell growth. *Cell* 2000; **103**: 253-262 [PMID: 11057898 DOI: 10.1016/s0092-8674(00)00117-3]

42 **Bruhn MA**, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. *Growth Factors* 2010; **28**: 394-408 [PMID: 20919962 DOI: 10.3109/08977194.2010.518616]

43 **Vasudevan KM**, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell* 2009; **16**: 21-32 [PMID: 19573809 DOI: 10.1016/j.ccr.2009.04.012]

44 **Murray NR**, Jamieson L, Yu W, Zhang J, Gökmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, Fields AP. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. *J Cell Biol* 2004; **164**: 797-802 [PMID: 15024028 DOI: 10.1083/jcb.200311011]

45 **Liu Y**, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. *J Biol Chem* 2004; **279**: 45556-45563 [PMID: 15322124 DOI: 10.1074/jbc.M407701200]

46 **Morrison Joly M**, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. *Breast Cancer Res* 2017; **19**: 74 [PMID: 28666462 DOI: 10.1186/s13058-017-0868-8]

47 **Agarwal NK**, Chen CH, Cho H, Boulbès DR, Spooner E, Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. *Oncogene* 2013; **32**: 2521-2526 [PMID: 22777355 DOI: 10.1038/onc.2012.287]

48 **Hall A**. Rho GTPases and the actin cytoskeleton. *Science* 1998; **279**: 509-514 [PMID: 9438836 DOI: 10.1126/science.279.5350.509]

49 **Gulhati P**, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. *Cancer Res* 2011; **71**: 3246-3256 [PMID: 21430067 DOI: 10.1158/0008-5472.CAN-10-4058]

50 **Kim EK**, Yun SJ, Ha JM, Kim YW, Jin IH, Yun J, Shin HK, Song SH, Kim JH, Lee JS, Kim CD, Bae SS. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. *Oncogene* 2011; **30**: 2954-2963 [PMID: 21339740 DOI: 10.1038/onc.2011.22]

51 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

52 **Masui K**, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. *Cell Metab* 2013; **18**: 726-739 [PMID: 24140020 DOI: 10.1016/j.cmet.2013.09.013]

53 **Masui K,** Cavenee WK, and Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. *Brain Pathol* 2015; **25**: 755-759 [PMID: 26526943 DOI: 10.1111/bpa.12307]

54 **Gu Y**, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. *Mol Cell* 2017; **67**: 128-138.e7 [PMID: 28648777 DOI: 10.1016/j.molcel.2017.05.030]

55 **Chiang CT**, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. *Cancer Lett* 2018; **434**: 152-159 [PMID: 30036610 DOI: 10.1016/j.canlet.2018.07.025]

56 **Masui K**, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. *Proc Natl Acad Sci U S A* 2015; **112**: 9406-9411 [PMID: 26170313 DOI: 10.1073/pnas.1511759112]

57 **Tanaka K**, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. *Cancer Discov* 2011; **1**: 524-538 [PMID: 22145100 DOI: 10.1158/2159-8290.CD-11-0124]

58 **Llovet JM**, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2016; **2**: 16018 [PMID: 27158749 DOI: 10.1038/nrdp.2016.18]

59 **Hu J**, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. *Sci Rep* 2016; **6**: 20484 [PMID: 26857837 DOI: 10.1038/srep20484]

60 **Xu Z,** Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Cigliano A, Evert K, Pascale RM, Dombrowski F, Evert M, Chen X, Calvisi DF, and Chen X. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. *Hepatology* 2019; **70**: 1600-1613 [PMID: 31062368 DOI: 10.1002/hep.30697]

61 **Kaibori M**, Shikata N, Sakaguchi T, Ishizaki M, Matsui K, Iida H, Tanaka Y, Miki H, Nakatake R, Okumura T, Tokuhara K, Inoue K, Wada J, Oda M, Nishizawa M, Kon M. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. *Dig Dis Sci* 2015; **60**: 919-928 [PMID: 25371154 DOI: 10.1007/s10620-014-3417-7]

62 **Villanueva A**, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology* 2008; **135**: 1972-1983, 1983.e1-1983.11 [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008]

63 **Calvisi DF**, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 1071-1083 [PMID: 21147110 DOI: 10.1053/j.gastro.2010.12.006]

64 **Galicia VA**, He L, Dang H, Kanel G, Vendryes C, French BA, Zeng N, Bayan JA, Ding W, Wang KS, French S, Birnbaum MJ, Rountree CB, Stiles BL. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. *Gastroenterology* 2010; **139**: 2170-2182 [PMID: 20837017 DOI: 10.1053/j.gastro.2010.09.002]

65 **Xu Z,** Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, and Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. *Exp Mol Med* 2018; **50**: e417 [PMID: 29303510 DOI: 10.1038/emm.2017.158]

66 **Guri Y**, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Jenoe P, Heim MH, Riezman I, Riezman H, Hall MN. mTORC2 Promotes Tumorigenesis via Lipid Synthesis. *Cancer Cell* 2017; **32**: 807-823.e12 [PMID: 29232555 DOI: 10.1016/j.ccell.2017.11.011]

67 **Khan MW**, Biswas D, Ghosh M, Mandloi S, Chakrabarti S, Chakrabarti P. mTORC2 controls cancer cell survival by modulating gluconeogenesis. *Cell Death Discov* 2015; **1**: 15016 [PMID: 27551450 DOI: 10.1038/cddiscovery.2015.16]

68 **Chen BW**, Chen W, Liang H, Liu H, Liang C, Zhi X, Hu LQ, Yu XZ, Wei T, Ma T, Xue F, Zheng L, Zhao B, Feng XH, Bai XL, Liang TB. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. *Mol Cancer Ther* 2015; **14**: 1805-1815 [PMID: 26026051 DOI: 10.1158/1535-7163.MCT-15-0029]

69 **Reyes-Gordillo K,** Shah R, Arellanes-Robledo J, Cheng Y, Ibrahim J, and Tuma PL. Akt1 and Akt2 Isoforms Play Distinct Roles in Regulating the Development of Inflammation and Fibrosis Associated with Alcoholic Liver Disease. *Cells* 2019; **8** [PMID: 31671832 DOI:10.3390/cells8111337]

70 **Festuccia WT**. Regulation of Adipocyte and Macrophage Functions by mTORC1 and 2 in Metabolic Diseases. *Mol Nutr Food Res* 2021; **65**: e1900768 [PMID: 32103588 DOI: 10.1002/mnfr.201900768]

71 **Rawat S**, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. *J Virol* 2015; **89**: 999-1012 [PMID: 25355887 DOI: 10.1128/JVI.02440-14]

72 **Brenndörfer ED**, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. *Hepatology* 2009; **49**: 1810-1820 [PMID: 19475692 DOI: 10.1002/hep.22857]

73 **Bertuccio P**, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. *J Hepatol* 2019; **71**: 104-114 [PMID: 30910538 DOI: 10.1016/j.jhep.2019.03.013]

74 **Valle J**, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

75 **Zhang S,** Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, and Chen X. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. *J Hepatol* 2017; **67**: 1194-1203 [PMID: 28733220 DOI: 10.1016/j.jhep.2017.07.006]

76 **Lee D,** Do IG, Choi K, Sung CO, Jang KT, Choi D, Heo JS, Choi SH, Kim J, Park JY, Cha HJ, Joh JW, Choi KY, and Kim DS. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. *Mod Pathol* 2012; **25**: 131-139 [PMID: 21874010 DOI: 10.1038/modpathol.2011.133]

77 **Yokoi K**, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. *Oncol Rep* 2018; **39**: 843-850 [PMID: 29251327 DOI: 10.3892/or.2017.6153]

78 **Wang J**, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. *J Hepatol* 2019; **71**: 742-752 [PMID: 31195063 DOI: 10.1016/j.jhep.2019.05.027]

79 **Yang H,** Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G, and Chen Y. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. *Oncotarget* 2015; **6**: 6310-6325 [PMID: 25749036 DOI: 10.18632/oncotarget.3355]

80 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

81 **Shuhua W,** Chenbo S, Yangyang L, Xiangqian G, Shuang H, Tangyue L, and Dong T. Autophagy-related genes Raptor, Rictor, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma. *Hum Pathol* 2015; **46**: 1752-1759 [PMID: 26363527 DOI: 10.1016/j.humpath.2015.07.016]

82 **Guo Z**, Zhang X, Zhu H, Zhong N, Luo X, Zhang Y, Tu F, Zhong J, Wang X, He J, Huang L. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. *Oncol Rep* 2021; **45**: 523-534 [PMID: 33416177 DOI: 10.3892/or.2020.7890]

83 **Wang Q,** Zhu J, Wang YW, Dai Y, Wang YL, Wang C, Liu J, Baker A, Colburn NH, and Yang HS. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma. *Oncogene* 2017; **36**: 6225-6234 [PMID: 28692058 DOI: 10.1038/onc.2017.228]

84 **Reita D**, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D. Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. *Cancers (Basel)* 2019; **11** [PMID: 31627299 DOI: 10.3390/cancers11101581]

85 **Wong CK**, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Győrffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. *Mol Cancer Res* 2020; **18**: 414-423 [PMID: 31932471 DOI: 10.1158/1541-7786.MCR-19-0525]

86 **Ma R**, Feng Y, Lin S, Chen J, Lin H, Liang X, Zheng H, Cai X. Mechanisms involved in breast cancer liver metastasis. *J Transl Med* 2015; **13**: 64 [PMID: 25885919 DOI: 10.1186/s12967-015-0425-0]

87 **Morrison Joly M**, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. *Cancer Res* 2016; **76**: 4752-4764 [PMID: 27197158 DOI: 10.1158/0008-5472.CAN-15-3393]

88 **Miller TW**, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. *J Clin Oncol* 2011; **29**: 4452-4461 [PMID: 22010023 DOI: 10.1200/JCO.2010.34.4879]

89 **Miller TW**, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. *Breast Cancer Res* 2011; **13**: 224 [PMID: 22114931 DOI: 10.1186/bcr3039]

90 **Zhang F,** Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X, and Zhang N. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. *Cancer Res* 2010; **70**: 9360-9370 [PMID: 20978191 DOI: 10.1158/0008-5472.CAN-10-0207]

91 **Li H**, Lin J, Wang X, Yao G, Wang L, Zheng H, Yang C, Jia C, Liu A, Bai X. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. *Breast Cancer Res Treat* 2012; **134**: 1057-1066 [PMID: 22476852 DOI: 10.1007/s10549-012-2036-2]

92 **Zhang Z,** Yang M, Chen R, Su W, Li P, Chen S, Chen Z, Chen A, Li S, and Hu C. IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways. *Oncogene* 2014; **33**: 3374-3382 [PMID: 23975422 DOI: 10.1038/onc.2013.337]

93 **Chen S,** Han Q, Wang X, Yang M, Zhang Z, Li P, Chen A, Hu C, and Li S. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway. *Cell Death Dis* 2013; **4**: e842 [PMID: 24113176 DOI: 10.1038/cddis.2013.380]

94 **Daulat AM**, Bertucci F, Audebert S, Sergé A, Finetti P, Josselin E, Castellano R, Birnbaum D, Angers S, Borg JP. PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. *Dev Cell* 2016; **37**: 311-325 [PMID: 27184734 DOI: 10.1016/j.devcel.2016.04.011]

95 **Zhang S,** Qian G, Zhang QQ, Yao Y, Wang D, Chen ZG, Wang LJ, Chen M, and Sun SY. mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis. *Cancer Res* 2019; **79**: 3725-3736 [PMID: 31142514 DOI: 10.1158/0008-5472.CAN-19-0180]

96 **Aubin JM**, Rekman J, Vandenbroucke-Menu F, Lapointe R, Fairfull-Smith RJ, Mimeault R, Balaa FK, Martel G. Systematic review and meta-analysis of liver resection for metastatic melanoma. *Br J Surg* 2013; **100**: 1138-1147 [PMID: 23775340 DOI: 10.1002/bjs.9189]

97 **Tas F**, Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. *Melanoma Res* 2017; **27**: 134-139 [PMID: 28099368 DOI: 10.1097/CMR.0000000000000332]

98 **Laugier F**, Finet-Benyair A, André J, Rachakonda PS, Kumar R, Bensussan A, Dumaz N. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. *Oncotarget* 2015; **6**: 28120-28131 [PMID: 26356562 DOI: 10.18632/oncotarget.4866]

99 **Chen XY,** Li DF, Han JC, Wang B, Dong ZP, Yu LN, Pan ZH, Qu CJ, Chen Y, Sun SG, and Zheng QS. Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling. *Oncotarget* 2017; **8**: 34565-34575 [PMID: 28410220 DOI: 10.18632/oncotarget.16655]

100 **Liang X,** Sun R, Zhao X, Zhang Y, Gu Q, Dong X, Zhang D, Sun J, and Sun B. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway. *J Cell Mol Med* 2017; **21**: 3579-3591 [PMID: 28699701 DOI: 10.1111/jcmm.13268]

101 **Schmidt KM**, Dietrich P, Hackl C, Guenzle J, Bronsert P, Wagner C, Fichtner-Feigl S, Schlitt HJ, Geissler EK, Hellerbrand C, Lang SA. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis. *Neoplasia* 2018; **20**: 1198-1208 [PMID: 30404068 DOI: 10.1016/j.neo.2018.10.001]

102 **Guenzle J**, Akasaka H, Joechle K, Reichardt W, Venkatasamy A, Hoeppner J, Hellerbrand C, Fichtner-Feigl S, Lang SA. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. *Int J Mol Sci* 2020; **22** [PMID: 33375117 DOI: 10.3390/ijms22010030]

103 **Bianchi M**, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol* 2012; **23**: 973-980 [PMID: 21890909 DOI: 10.1093/annonc/mdr362]

104 **Pinotti E**, Montuori M, Giani A, Uggeri F, Garancini M, Gianotti L, Romano F. Surgical treatment of liver metastases from kidney cancer: a systematic review. *ANZ J Surg* 2019; **89**: 32-37 [PMID: 30685878 DOI: 10.1111/ans.15000]

105 **Sun B,** Chen L, Fu H, Guo L, Guo H, and Zhang N. Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma. *Tumour Biol* 2016; **37**: 4457-4466 [PMID: 26500094 DOI: 10.1007/s13277-015-4296-z]

106 **Bae SY,** Kim HJ, Lee KJ, and Lee K. Translationally controlled tumor protein induces epithelial to mesenchymal transition and promotes cell migration, invasion and metastasis. *Sci Rep* 2015; **5**: 8061 [PMID: 25622969 DOI: 10.1038/srep08061]

107 **Chen L**, Wang KJ, Li H. Re: Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma: S. Maru, Y. Ishigaki, N. Shinohara, T. Takata, N. Tomosugi and K. Nonomura J Urol 2013; 189: 1921-1929. *J Urol* 2013; **190**: 1957 [PMID: 23933458 DOI: 10.1016/j.juro.2013.04.135]

108 **Riihimäki M**, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. *Oncotarget* 2016; **7**: 52307-52316 [PMID: 27447571 DOI: 10.18632/oncotarget.10740]

109 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; **66**: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]

110 **Bian YH**, Xu J, Zhao WY, Zhang ZZ, Tu L, Cao H, Zhang ZG. Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer. *Am J Transl Res* 2017; **9**: 4317-4330 [PMID: 28979705 DOI: 10.21203/rs.3.rs-27425/v1]

111 **Wang YG,** Xu L, Jia RR, Wu Q, Wang T, Wei J, Ma JL, Shi M, and Li ZS. DDR2 Induces Gastric Cancer Cell Activities via Activating mTORC2 Signaling and Is Associated with Clinicopathological Characteristics of Gastric Cancer. *Dig Dis Sci* 2016; **61**: 2272-2283 [PMID: 27010547 DOI: 10.1007/s10620-016-4116-3]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflicting interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 25, 2021

**First decision:** April 19, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Germany

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Rodrigues PM **S-Editor:** Wang LL **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**

****

**Figure 1 Mechanism by which mammalian target of rapamycin complex 2 participates in tumorigenesis.** mTOR: Mammalian target of rapamycin; mTORC2: mTOR complex 2.

****

**Figure 2 Mechanism by which mammalian target of rapamycin complex 2 participates in metastasis.** mTOR: Mammalian target of rapamycin; mTORC2: mTOR complex 2.

****

**Figure 3 Mechanism by which mammalian target of rapamycin complex 2 is involved in tumorigenesis of primary liver cancer.** HCC: Hepatocellular carcinoma; iCCC: Intrahepatic cholangiocellular carcinoma; mTOR: Mammalian target of rapamycin; mTORC2: mTOR complex 2.

**Table 1 Overexpression of mammalian target of rapamycin complex 2 and its mediators determine clinical outcome**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **mTORC2 mediator** | **Associated with** | **Measured by** | **Ref.** |
| Primary liver cancer | HCC | p-AKTSer473 overexpression | poor outcome (*P* < 0.02) | IHC | Hu *et al*[59] |
|  |  | Rictor overexpression | Reduced OS (*P* = 0.0029) | mRNA expression | Xu *et al*[60] |
|  |  | Rictor overexpression | Reduced RFS (*P* = 0.016) | IHC, mRNA expression | Kaibori *et al*[61] |
|  | iCCC | p-AKT1 overexpression | Improved OS (*P* = 0.0137) | IHC | Lee *et al*[76] |
|  | CRLM | Data only available for primary CRC | | | |
|  |  | Rictor expression | Increasing tumor stage | mRNA expression | Gulhati *et al*[49] |
|  |  | Rictor expression | Increasing tumor stage | IHC, mRNA expression | Shuhua *et al*[81] |
|  |  | Rictor expression | Reduced OS (*P* = 0.0004) | IHC | Wang *et al*[10] |
| Secondary liver cancer | Breast cancer liver metastases | Data only available for invasive ductal breast carcinoma | | | |
|  |  | Rictor expression | Lymph node metastasis | IHC | Zhang *et al*[90] |
|  | Melanoma liver metastases | Rictor positivity (primary tumor) | Reduced OS (*P* = 0.018) | IHC | Liang *et al*[100] |
|  |  | Rictor expression | Tumor stage/metastatic disease | mRNA expression | Schmidt *et al*[101] |
|  | Renal cancer liver metastases | No data available | | | |
|  | Gastric cancer liver metastases | Data only available for gastric cancer | | | |
|  |  | Rictor, p-AKTSer437 expression | Tumor stage, reduced RFS and OS | IHC | Bian *et al*[7] |
|  |  | Rictor expression | tumor stage, reduced RFS and OS (*P* = 0.012, *P* = 0.014) | IHC | Bian *et al*[110] |
|  | Pancreatic cancer liver metastases | Data only available for pancreatic cancer | | | |
|  |  | Rictor expression | Reduced OS | IHC | Schmidt *et al*[9] |

CRC: Colorectal cancer; CRLM: Colorectal liver metastases; HCC: Hepatocellular carcinoma; iCCC: Intrahepatic cholangiocarcinoma; IHC: Immunohistochemistry; mTORC2: Mammalian target of rapamycin complex 2; OS: Overall survival; RFS: Recurrence-free survival.